Crucially, whether these genes influence tumor development through established pathways—FcεRI signaling (MS4A2), Integrin-β1/FAK (IGSF10), or ERK transduction (MFAP3L)—requires further validation, as does their relationship with MSC activity. The gene discussed is MS4A2; the disease is neoplasm.